Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herombopag for prevention of chemotherapy-induced thrombocytopenia in gastrointestinal tumors
ChiCTR2500106644Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT) and gastrointestinal neoplasia, sponsored by Changhai Hospital. Primary endpoint: blood platelet count at day 21. Started Jul 2025; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)gastrointestinal neoplasia
Beyond the preview
Go deeper on ChiCTR2500106644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106644.